EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Digital Transformation in Pharma Manufacturing | David Holt, FactoryTalk | ISPE 2026 | Pharma Focus Asia
Group Executive Director, FactoryTalk
David Holt is the Group Managing Director at Factory Talk with extensive leadership experience across multiple industries He focuses on innovative software solutions that enable the digital transformation of operations within GxP pharmaceutical and medical deviceregulated industries
Articles
Labelling and imaging of Radiopharmaceuticals
A radiopharmaceutical is a radioactive compound used for the diagnosis and treatment of human diseases In nuclear medicine nearly of the radiopharmaceuticals are used for diagnostic purposes while the rest are used for treatment It is a relatively new modality
Research Insights
When procedures meet practice in community pharmacies: qualitative insights from pharmacists and pharmacy support staff
Abstract Objectives Our aim was to explore how members of community pharmacy staff perceive and experience the role of procedures within the workplace in community pharmacies Setting Community pharmacies in England and Wales
Case Studies
Novel Vaccines - Heat Stable Anthrax Vaccine
Challenge Existing approved Anthrax vaccines are based on cellfree filtrates of disintegrated cells of Bacillus anthracis adsorbed onto an aluminiumhydrogel adjuvant A number of side effects are attributed to these vaccines including poor safety profile and a low immunogenicity necessitating repea
Techno Trends
Novo Nordisk Introduced First and Only Awiqli® for Type 2 Diabetes
Novo Nordisk has introduced Awiqli insulin icodecabae the first and only onceweekly basal insulin for adults with type diabetes
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Why tier-2 and tier-3 cities are not included for clinical research
Co-Founder at DPHS Pvt. Ltd., Dr. Krutikesh Age is a researcher and a visionary committed towards propelling the field of clinical research and healthcare expansion in India. As the Co-founder of DPHS, Krutikesh manages varied key roles including Leadership, developing business and marketing strategies and Networking to name a few. It is through the deep understanding of clinical research and market dynamics that he has been instrumental in expanding the operations of DPHS in the past few years.
Revolutionising Drug Discovery and Development with Artificial Intelligence
13+ years of healthcare and life sciences industry experience in growth consulting and market intelligence. Aarti Chitale has a strong understanding of pharma and biopharma industry especially the Technology enabled Drug Discovery and Development and Contract Pharma services Industry with keen interest in Emerging Business Models and new growth avenues.
Analysis of Blood Microbiota Compositionin Cardiovascular Disease Patients
Dr. Ikram Khan, the first author of the Article, Studying Medical Microbiology in Lanzhou University China as a PhD student, and working on blood microbial Ecology and their association with cardiovascular disease. In March 2022, we published two Articles on this work. Email: ikram2018@lzu.edu.cn
Assistant Professor Imran Khan, 2nd Author of this article, Supervises BS(Hons) students and is engaged in the teaching and research of Bacteriology, Nano-medicine, and Molecular Biology. Presently working as, a member of Quality Enhancement Cell at Xcito School of Nursing and Allied Health Sciences Pakistan. Email:Imran.mic727@gmail.com
Professor Zhou Jianye, is also Co-supervisor of this study, and supervises Master students. He Engaged in the Teaching and Research of Stomatology and Microbial Ecology at School of Northwest Minzu University”.Email: 14092785@qq.com
Professor Xie Ping, supervises Master and PhD students.She has long been engaged in the research of cardiovascular disease pathogenesis and drug prevention. Her current status is “Director of Cardiovascular Center of Gansu Provincial Hospital”.
Professor Li Zhiqiang, is a Co-supervisor of this study, and supervises Master and PhD students. He Engaged in the Teaching and Research of Stomatology and Microbial Ecology. His current status is “Director of graduate School of Northwest Minzu University”. Email: Lizhiqiang6767@163.com
Professor An Lizhe, supervise this work as a First Supervisor. He supervises PhD and doctoral students, and engaged in the Teaching and Research of Molecular Biology, Environmental Botany and Ecology. Currently working as, a President and Deputy Secretary of the Party Committee of Beijing Forestry University. Email: yxlzq@xbmu.edu.cn
Dr. Zhang Xiaowei is a professor, chief physician, director of the second ward of cardiovascular medicine, and deputy director of the Science and Technology Department. He has completed projects such as epidemiological investigation and prevention plan research of hypertension in Gansu Province and has published many SCI and CSCD papers, and currently undertakes 1st national natural science foundation, 2nd provincial natural science foundations, and 1st municipal science foundation.
Nanovaccines
Dr. Priya Gupta is currently working as an Assistant Professor at Amity Institute of Pharmacy, Amity University, Noida and earned her Ph.D. in Pharmaceutics from Jamia Hamdard in 2024. Her area of research includes formulation development, novel drug delivery systems, nanoformulations. She has authored more than 15 articles in peer-reviewed national and international journals.
Dr. Disha Marwaha earned a Ph.D. in Biological Sciences from the CSIR-Central Drug Research Institute (CSIR-CDRI) in 2024 and currently serves as an Assistant Professor at Chandigarh University Uttar Pradesh. Her research encompasses nanomedicine, pharmacokinetics, formulation development, and targeted drug delivery systems. She has authored more than 22 articles in peer-reviewed international journals.
The Past, Present, and Future of Sickle-cell Disease Registries: Findings from a Global Review
Sam is an Associate Director in Patient-Centered Research at Vitaccess, providing direction and oversight across their health economics and outcomes research, patient-centered outcomes, and real-world evidence portfolio. Sam joined Vitaccess in 2018, after spending three years as a project manager within the PCO group at a leading contract research organisation.
Fatemeh is a Medical Writer at Vitaccess. She plays a key role in their digital real-world evidence studies, developing materials that range from client-facing deliverables through to content communicating the value and progress of studies to clinical experts, patient representatives, and participants.
Oktawia is a Research Associate at Vitaccess, contributing to their patient-reported outcomes and clinical outcome assessment projects and supporting the development, effective delivery, and quality of their real-world studies. Oktawia has experience in health research from previous roles involving healthcare technologies, a medical ventures accelerator, and her doctoral research studies.
Akosua is an Associate Consultant at Vitaccess, currently project managing a range of their longitudinal and cross-sectional real-world evidence studies. She has experience in developing evidence-generation strategies for clients, including gap analyses for health technology assessment submissions and the reimbursement of digital health technologies.
press releasesRead more...
Innovent Biologics announced a strategic collaboration with Eli Lilly on research and development and licensing.
Innovent Biologics SSE HKSE a hightech biopharmaceutical company today announced a strategic collaboration agreement with Eli Lilly and Company for research and licensing focusing on the development of innovative drugs
Cellares and Seoul National University Hospital Launch Proof-of-Concept for Automated Manufacturing of Gene-Modified HSPC Therapy on the Cell Shuttle® Platform
Cellares the first Integrated Development and Manufacturing Organization IDMO and Seoul National University Hospital SNUH a leading translational medical center in South Korea today announced a partnership
Zymeworks Completes Acquisition of Theravance Biopharma
Zymeworks Inc Nasdaq ZYME a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel multifunctional biotherapeutics today completed
UofG announces second research collaboration with Eli Lilly and Company for immune-related diseases
Worldchanging experts at the University of Glasgow will partner with scientists at leading pharmaceutical company Eli Lilly and Company Lilly to tackle immunerelated diseases
Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
Thermo Fisher Scientific the world leader in serving science today announced the Gibco CHOK Catalog Panel a cGMPready portfolio of basal and feed media designed to support strong
Oracle Partners with Wipro to Strengthen End-to-End Pharmacovigilance Services
Oracle Life Sciences announced a partnership with Wipro Limited a leading AIpowered technology services and consulting company to strengthen Wipros pharmacovigilance PV service offering using Oracle Life
EventsRead more...
28 - 01
Sep 2026Discovery on Target 2026
Boston, MA, USA
29 - 01
Sep 202610th IPF Summit 2026
Boston, MA, USA
29 - 01
Sep 2026Powtech Technopharm 2026
Nuremberg, Germany
30 - 01
Sep 2026Pharma Launch Excellence Summit
Hyatt Regency Boston Harbor, B...
01 - 01
Oct 2026Articulate 2026: The Communication Revolution
Philadelphia, United States
05 - 06
Oct 2026ISPSAI France 2026
Paris, France
05 - 08
Oct 202616th World CB & CDx Summit 2026
Boston, MA, USA
12 - 13
Oct 2026Pharmaceutics 2026
Village Hotel Changi, Singapor...
LATEST NEWSRead more...
Turbine and Daiichi Sankyo Expand ADC Discovery Collaboration
Turbine and Daiichi Sankyo have expanded their collaboration to support antibodydrug conjugate ADC discovery using computational modelling
TriSalus Receives FDA Clearance for TriNav Advance for Liver Embolisation
TriSalus Life Sciences has received k clearance from the US Food and Drug Administration FDA for TriNav Advance a new device within its PressureEnabled Drug Delivery PEDD portfolio for liverdirected embolisation procedures
SK pharmteco and GEMMABio Expand Manufacturing Collaboration for SMA Gene Therapy
SK pharmteco and Gemma Biotherapeutics GEMMABio have expanded their manufacturing collaboration to support the clinical development of GB an investigational gene therapy for spinal muscular atrophy type SMA
Merck’s KEYTRUDA QLEX Approved for Subcutaneous Administration
Merck has announced that Japans Ministry of Health Labour and Welfare MHLW has approved KEYTRUDA QLEX pembrolizumab and berahyaluronidase alfapmph for subcutaneous administration
Dualitas Therapeutics and Roche Partner to Discover Bispecific Antibodies for I&I Diseases
Dualitas Therapeutics has announced a research collaboration and licence agreement with Roche to discover and develop novel bispecific antibody BsAb therapies for immunology and inflammation II diseases
Eisai and Biogen Receive Approval for LEQEMBI Pen for Early Alzheimer’s Disease
Eisai and Biogen have received approval in Japan for LEQEMBI Pen a subcutaneous SC formulation of lecanemab for the treatment of early Alzheimers disease AD